Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.
Type:
Grant
Filed:
November 13, 2020
Date of Patent:
May 14, 2024
Assignees:
ST CUBE INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Stephen S. Yoo, Ezra M. Chung, Yong-Soo Kim, Seung-Oe Lim, Chia-Wei Li, Mien-Chie Hung
Abstract: Disclosed herein are agnostic anti-CD40 antibodies and methods of using such for eliciting CD40 signaling, thereby enhancing immune responses, such as dendritic cell functions. The antibodies disclosed herein may be used to treat diseases, such as cancer and immune disorders.
Abstract: The present invention relates to an epitope on fibronectin B (ED-B) domain, more specifically to an antibody or an antibody fragment of ED-B domain, and can be widely applied in in-vitro detection and in-vivo positioning of ED-B domain as well as in targeted cancer therapy.
Type:
Grant
Filed:
November 5, 2021
Date of Patent:
April 30, 2024
Assignee:
Hefei Lifeon Pharmaceutical Co., Ltd.
Inventors:
Mei Zhang, Junqiu Ji, Meihua Gao, Jun Chen
Abstract: The present disclosure concerns antibodies specific for the Na v.7 polypeptides which are capable of antagonizing the biological activity of the Na v.7 polypeptide. The anti-Na v.7 antibodies can be used for alleviating the symptoms of pain and/or for treating or alleviating the symptoms of an hyperproliferative disease. The presence disclosure also concerns immunogens and methods for making antibodies, such as the anti-Na v.7 antibodies, comprising a single-domain antibody.
Type:
Grant
Filed:
May 17, 2019
Date of Patent:
April 2, 2024
Assignee:
NATIONAL RESEARCH COUNCIL OF CANADA
Inventors:
Marzia Martina, Balu Chakravarthy, Yves Durocher, Mehdi Arbabi-Ghahroudi, Anne Marcil, Danica Stanimirovic, Traian Sulea, Maria Moreno, Umberto Banderali
Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.
Type:
Grant
Filed:
November 13, 2020
Date of Patent:
March 19, 2024
Assignees:
STCUBE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS
Inventors:
Stephen S. Yoo, Ezra M. Chung, Yong-Soo Kim, Mien-Chie Hung, Chia-Wei Li, Seung-Oe Lim
Abstract: Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.
Type:
Grant
Filed:
March 8, 2022
Date of Patent:
March 19, 2024
Assignee:
Janssen Biotech, Inc.
Inventors:
Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
Abstract: A method of treating pulmonary metastasis of osteosarcoma cells (pOSs) in a subject in need thereof includes administering to the subject a therapeutically effective amount of an agent that interferes with VCAM-1/?4?1 signaling between pOSs expressing VCAM-1 and pulmonary macrophages (MACs) expressing ?4?1.
Abstract: Described herein are doppel-targeting molecules (e.g., antibodies) useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
Type:
Grant
Filed:
June 17, 2021
Date of Patent:
February 27, 2024
Assignee:
PHAROSGEN CO., LTD
Inventors:
Youngro Byun, Ha Kyeong Lee, So Young Choi, So Ra Park, Se Ra Lee, Seung Il Baek
Abstract: Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.
Type:
Grant
Filed:
August 26, 2021
Date of Patent:
February 13, 2024
Assignee:
Duke University
Inventors:
Edward F. Patz, Jr., Michael J. Campa, Elizabeth Gottlin, Barton F. Haynes, Hua-Xin Liao, M. Anthony Moody
Abstract: A method for treating a human patient suffering from fistulizing Crohn's disease, comprising administering to a patient suffering from fistulizing Crohn's disease, a humanized antibody having binding specificity for human ?4?7 integrin, wherein the human patient has a seton that was surgically placed prior to administration of the antibody, and wherein the dosing regimen induces fistula(e) healing.
Abstract: The present invention provides a method for the treatment of a patient comprising administering to the patient an initial dose of between about 1 mg and about 150 mg of a MAdCAM antagonist antibody. Biomarkers for assessing a patient's response to anti-MAdCAM treatment are also provided.
Type:
Grant
Filed:
November 30, 2020
Date of Patent:
January 30, 2024
Assignee:
Pfizer Inc.
Inventors:
Fabio Cataldi, Robert A. Clare, Gail M. Comer, Vivekananda Pradhan, Alaa Ahmad, Mina Hassan-Zahraee, Mera Krishnan Tilley, Weidong Zhang, Anindita Banerjee, Karen Michelle Page, Michael Steven Vincent, David J. Von Schack
Abstract: The present invention relates to novel bispecific polypeptides, such as antibodies, and their use in the treatment of cancers, particularly cancers expressing carcinoembryonic antigen (CEA).
Type:
Grant
Filed:
November 4, 2022
Date of Patent:
January 16, 2024
Assignee:
ALLIGATOR BIOSCIENCE AB
Inventors:
Peter Ellmark, Karin Hagerbrand, Laura Varas, Mattias Levin, Anna Säll, Laura von Schantz
Abstract: The present invention relates to immunoconjugates, compositions, methods and uses for treating brain tumors, especially glioma, by administration of a tumour necrosis factor alpha (TNF?) immunoconjugate.
Abstract: The present invention provides an antibody to a fibrosis-related molecule and medical application thereof. The antibody of the present invention is an antibody that binds to CHL1 protein and an antibody that neutralizes the binding of the CHL1 protein to a fibroblast.
Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
Type:
Grant
Filed:
February 16, 2021
Date of Patent:
January 2, 2024
Assignee:
Bristol-Meyers Squibb Company
Inventors:
Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.
Type:
Grant
Filed:
April 15, 2019
Date of Patent:
January 2, 2024
Assignees:
National University Corporation Okayama University, Niigata University, National University Corporation Gunma University
Abstract: The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.
Type:
Grant
Filed:
September 14, 2021
Date of Patent:
December 19, 2023
Assignee:
Celros Biotech
Inventors:
Yun Soo Bae, Eunjung An, Jung-Yeon Yoo, Hyunbo Shim, Hye Eun Lee
Abstract: In certain aspects, provided herein are inhibitory anti-ENPP1 antibodies and antigen binding fragments thereof. In some aspects, provided herein are methods of treating myocardial infarction using the antibodies provided herein. In certain aspects, provided herein are nucleic acid molecules encoding the antibodies provided herein, host cells comprising such nucleic acids, and methods of making the antibodies provided herein using such host cells. In some aspects, also provided herein are pharmaceutical compositions comprising the antibodies provided herein.
Type:
Grant
Filed:
May 3, 2021
Date of Patent:
December 5, 2023
Assignee:
The Regents of the University of California
Abstract: There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.
Type:
Grant
Filed:
April 13, 2021
Date of Patent:
November 14, 2023
Inventors:
Kim Suzanne Midwood, Philip Antony Bland-Ward, Nigel Burns, Patrick John Hextall, Susan Rebecca Aungier
Abstract: Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.
Type:
Grant
Filed:
April 21, 2021
Date of Patent:
November 7, 2023
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Jie Liu, Irving L. Weissman, Ravindra Majeti